Attached Carole Ho - 12 Aug 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
12 Aug 2025
Net transactions value
-$51,684
Form type
4
Filing time
14 Aug 2025, 20:33:05 UTC
Previous filing
07 Aug 2025
Next filing
06 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ho Carole Chief Medical Officer C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO /s/ Tyler Nielsen, by power of attorney 14 Aug 2025 0001724605

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $39,884 -2,937 -1.3% $13.58 217,391 12 Aug 2025 Direct F1, F2, F3
transaction DNLI Common Stock Sale $11,800 -806 -0.37% $14.64 216,585 13 Aug 2025 Direct F3, F4
holding DNLI Common Stock 183,219 12 Aug 2025 See footnote F5
holding DNLI Common Stock 25,000 12 Aug 2025 See footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 128,405 Unvested RSUs.
F4 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
F5 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F6 The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.